Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis.

Lucia Lisi, Pierluigi Navarra, Cinzia Dello Russo, Roberto Cirocchi, Egidio Stigliano, A. Sharp, D. L. Feinstein

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

43 Citazioni (Scopus)

Abstract

Current treatments used in Multiple Sclerosis (MS) are partly effective in the early stages of the disease but display very limited benefits in patients affected by progressive MS. One possible explanation is that these therapies are unable to target the inflammatory component most active during the progressive phase of the disease, and compartmentalized behind the blood-brain barrier. Our findings show that Rapamycin ameliorates clinical and histological signs of chronic EAE when administered during ongoing disease. Moreover, Rapamycin significantly reduced the hyperalgesia observed before clinical development of EAE which, in turn, is completely abolished by the administration of the drug.
Lingua originaleEnglish
pagine (da-a)43-51
Numero di pagine9
RivistaJournal of Neuroimmunology
DOI
Stato di pubblicazionePubblicato - 2012

Keywords

  • EAE
  • Myelin
  • Neuropathic pain
  • Progressive MS
  • Rapamycin
  • mTOR

Fingerprint

Entra nei temi di ricerca di 'Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis.'. Insieme formano una fingerprint unica.

Cita questo